Aurora, CO, January 5, 2005Â GlobeImmune, Inc., a development-stage biopharmaceutical company, today announced the appointment of two management team members. “We are pleased that GlobeImmune has been able to fill these two key positions,” said Timothy C. Rodell, M.D., GlobeImmune’s Chief Executive Officer. “The addition of these talented individuals to our management team provides important expertise for the Company and will help GlobeImmune to successfully develop and commercialize our products and technology.”
David Apelian, M.D., Ph.D., M.B.A., has accepted the position of Vice President of Clinical Development and Regulatory Affairs and Chief Medical Officer. Dr. Apelian’s therapeutic area experience includes inflammatory bowel disease, hepatitis C and hepatitis B. Dr. Apelian comes to GlobeImmune from Bristol-Myers Squibb where he was Clinical Director in the Department of Clinical Design and Evaluation/Infectious Diseases Group and medical lead for clinical development for the NDA filing of entecavir for chronic HBV. Prior to that, he served as Clinical Director in the Department of Hepatology/Gastroenterology at Schering Plough where he was medical lead on the pediatric sNDA for Rebetron for chronic HCV. Dr. Apelian received his Ph.D. in Biochemistry from Rutgers University, his M. D. from the University of Medicine and Dentistry of New Jersey and an M.B.A. from Quinnipiac University. He completed residency training in pediatrics at New York Hospital, Cornell Medical Center, and is board certified in Pediatrics.
Kirk Christoffersen, M.B.A., has been named Senior Director, Corporate Development. Mr. Christoffersen has over eight years experience in biotechnology-related corporate development and marketing with OSI Pharmaceuticals, Gilead Sciences, and Ribozyme Pharmaceuticals. During his tenure, Mr. Christoffersen completed a number of transactions including product in- and out-licensing, research and commercial alliances, and corporate acquisitions. Most recently, Mr. Christoffersen served as the Gelclair® Brand Leader, launching the product to OSI Pharmaceutical’s sales team.
About GlobeImmune
GlobeImmune, Inc. is an early-stage biopharmaceutical company pioneering the development of potent, targeted molecular immunotherapies for the treatment of cancer and infectious diseases. The Company’s first products for the treatment of cancers of the lung and gastrointestinal tract are currently in Phase 1 clinical trials. For additional information, please visit the Company’s website at https://globeimmune.com/. GlobeImmune is headquartered at the Fitzsimons BioScience Park in Aurora, Colorado.
Contact:
Timothy C. Rodell, M.D, CEO
GlobeImmune, Inc.
720-859-4070